Update and rationale for ongoing acute myocardial infarction trials: Combination therapy, facilitation, and myocardial preservation - 17/08/11
Doi : 10.1016/j.ahj.2006.04.011
Howard C. Herrmann, MD ⁎ 
Cardiac Catheterization Laboratories, Hospital of the University of Pennsylvania, Philadelphia, PA
⁎Reprint requests: Howard C. Herrmann, MD, Director, Cardiac Catheterization Laboratories, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104.
Riassunto |
Advancements in the treatment of myocardial infarction such as coronary care units, patient education, improved emergency response systems, and reperfusion therapy have reduced mortality. However, in an effort to further reduce the present rate by improving patency rates and microcirculatory perfusion, by better preserving myocardium, and/or treating shock more effectively, more research is under way to improve strategies now in place and to develop new, more effective ways to treat these patients.
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2006
Pubblicato da Elsevier Masson SAS.
Vol 151 - N° 6S
P. S30-S39 - Giugno 2006 Ritorno al numero
Articolo precedente
- Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction
- Duane S. Pinto, Matthew Southard, Lauren Ciaglo, C. Michael Gibson
- To obtain continuing medical education credit
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?